Catching the therapeutic window of opportunity in early crohn’s disease

Current Drug Targets

Volumn 15, Issue 11, 2014, Pages 1056-1063

  Danese, Silvio ^a   Fiorino, Gionata ^a   Fernandes, Carlos ^b   Peyrin Biroulet, Laureal ^c  

^a HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^b CENTRO HOSPITALAR DE VILA NOVA DE GAIA ESPINHO   (Portugal)

^c UNIVERSITY HOSPITAL OF NANCY   (France)

Author keywords

Crohn s disease; Early disease; Inflammatory bowel disease; Therapy

Indexed keywords

AZATHIOPRINE; C REACTIVE PROTEIN; CALGRANULIN; CERTOLIZUMAB PEGOL; CORTICOSTEROID; INFLIXIMAB; LACTOFERRIN; MERCAPTOPURINE;

ANKYLOSING SPONDYLITIS; ARTICLE; CROHN DISEASE; DISEASE COURSE; EARLY DIAGNOSIS; EARLY INTERVENTION; HEALTH CARE QUALITY; HUMAN; IRRITABLE COLON; MULTICENTER STUDY (TOPIC); PSORIATIC ARTHRITIS; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REMISSION; RHEUMATOID ARTHRITIS; TREATMENT OUTCOME;

EID: 84925857082     PISSN: 13894501     EISSN: 18735592     Source Type: Journal    
DOI: 10.2174/1389450115666140908125738     Document Type: Article

References (78)

1. Louis E, Collard A, Oger AF, et al. Behaviour of Crohn's disease according to the Vienna classification: changing pattern over the course of the disease. Gut 2001; 49(6): 777-82.
2. Cosnes J, Cattan S, Blain A, et al. Long-term evolution of disease behavior of Crohn's disease. Inflamm Bowel Dis 2002; 8(4): 244-50.
3. Sands BE. From symptom to diagnosis: clinical distinctions among various forms of intestinal inflammation. Gastroenterology. [Research Support, U. S. Gov't, P. H. S. Review]. 2004; 126(6): 1518-32.
4. Nahon S, Lahmek P, Lesgourgues B, et al. Diagnostic delay in a French cohort of Crohn's disease patients. J Crohns Colitis 2014; 8(9): 964-9.
5. Schoepfer AM, Dehlavi MA, Fournier N, et al. Diagnostic delay in Crohn's disease is associated with a complicated disease course and increased operation rate. Am J Gastroenterol 2013; 108(11): 1744-53.
6. Furfaro F, Sciurti R, Bezzio C, et al. Impact of diagnostic delay on clinical outcome of Crohn's disease. J Crohns Colitis 2014; ECCO congress.
7. Lichtenstein GR, Hanauer SB, Sandborn WJ. Management of Crohn's disease in adults. The American journal of gastroenterology. [Practice Guideline] 2009; 104(2): 465-83; quiz 4, 84.
8. Bouguen G, Peyrin-Biroulet L. Surgery for adult Crohn's disease: what is the actual risk? Gut 2011; 60(9): 1178-81.
9. Peyrin-Biroulet L, Harmsen WS, Tremaine WJ, Zinsmeister AR, Sandborn WJ, Loftus EV, Jr. Surgery in a population-based cohort of Crohn's disease from Olmsted County, Minnesota (1970-2004). Am J Gastroenterol 2012; 107(11): 1693-701.
10. Pineton de Chambrun G, Peyrin-Biroulet L, Lemann M, Colombel JF. Clinical implications of mucosal healing for the management of IBD. Nat Rev Gastroenterol Hepatol 2010; 7(1): 15-29.
11. Schnitzler F, Fidder H, Ferrante M, et al. Mucosal healing predicts long-term outcome of maintenance therapy with infliximab in Crohn's disease. Inflamm Bowel Dis 2009; 15(9): 1295-301.
12. Pariente B, Cosnes J, Danese S, et al. Development of the Crohn's disease digestive damage score, the Lemann score. Inflamm Bowel Dis 2011; 17(6): 1415-22.
13. Gower-Rousseau C, Savoye G, Colombel JF, Peyrin-Biroulet L. Are we improving disease outcomes in IBD? A view from the epidemiology side. Gut 2014; 63(10): 1529-30.
14. Feagan BG, Panaccione R, Sandborn WJ, et al. Effects of adalimumab therapy on incidence of hospitalization and surgery in Crohn's disease: results from the CHARM study. Gastroenterology 2008; 135(5): 1493-9.
15. Lichtenstein GR, Yan S, Bala M, Blank M, Sands BE. Infliximab maintenance treatment reduces hospitalizations, surgeries, and procedures in fistulizing Crohn's disease. Gastroenterology 2005; 128(4): 862-9.
16. Puolakka K, Kautiainen H, Mottonen T, et al. Early suppression of disease activity is essential for maintenance of work capacity in patients with recent-onset rheumatoid arthritis: five-year experience from the FIN-RACo trial. Arthritis Rheum 2005; 52(1): 36-41.
17. Contreras-Yanez I, Rull-Gabayet M, Pascual-Ramos V. Early disease activity suppression and younger age predict excellent outcome of recent-onset rheumatoid arthritis patients treated with conventional disease modifying anti-rheumatic drugs. Clin Exp Rheumatol 2012; 30(3): 402-8.
18. Sandborn WJ, Hanauer S, Van Assche G, et al. Treating beyond symptoms with a view to improving patient outcomes in inflammatory bowel diseases. J Crohns Colitis 2014; 8(9): 927-35.
19. Rutgeerts P, Van Assche G, Sandborn WJ, et al. Adalimumab induces and maintains mucosal healing in patients with Crohn's disease: data from the EXTEND trial. Gastroenterology 2012; 142(5): 1102-11 e2.
20. Colombel JF, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med 2010; 362(15): 1383-95.
21. D'Haens G, Baert F, van Assche G, et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet 2008; 371(9613): 660-7.
22. Schreiber S, Colombel JF, Bloomfield R, et al. Increased response and remission rates in short-duration Crohn's disease with subcutaneous certolizumab pegol: an analysis of PRECiSE 2 randomized maintenance trial data. Am J Gastroenterol 2010; 105(7): 1574-82.
23. Lennard-Jones JE, Shivananda S. Clinical uniformity of inflammatory bowel disease a presentation and during the first year of disease in the north and south of Europe. EC-IBD Study Group. Eur J Gastroenterol Hepatol 1997; 9(4): 353-9.
24. Reinisch S, Schweiger K, Collet-Fenetrier B, Peyrin-Biroulet L, Panés J, Reinisch. Sensitivity of Lennard-Jones criteria in the diagnosis of Crohn's disease. J Crohns Colitis 2014; ECCO congress 2014.
25. Munkholm P. Crohn's disease-occurrence, course and prognosis. An epidemiologic cohort-study. Dan Med Bull 1997; 44(3): 287-302.
26. Langholz E. Ulcerative colitis. An epidemiological study based on a regional inception cohort, with special reference to disease course and prognosis. Dan Med Bull 1999; 46(5): 400-15.
27. Vind I, Riis L, Jess T, et al. Increasing incidences of inflammatory bowel disease and decreasing surgery rates in Copenhagen City and County, 2003-2005: a population-based study from the Danish Crohn colitis database. Am J Gastroenterol 2006; 101(6): 1274-82.
28. Stange EF, Travis SP, Vermeire S, et al. European evidence based consensus on the diagnosis and management of Crohn's disease: definitions and diagnosis. Gut. [Consensus Development Conference Research Support, Non-U. S. Gov't] 2006; 55 Suppl 1: i1-15.
29. Mottonen T, Hannonen P, Korpela M, et al. Delay to institution of therapy and induction of remission using single-drug or combination-disease-modifying antirheumatic drug therapy in early rheumatoid arthritis. Arthritis Rheum 2002; 46(4): 894-8.
30. Sorensen J, Hetland ML. Diagnostic delay in patients with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis: results from the Danish nationwide DANBIO registry. Ann Rheum Dis 2014 Feb 17. [Epub ahead of print].
31. European report. [20 July 2014]; Available from: http://efccasolutions. net/european. php.
32. Albert JG, Kotsch J, Kostler W, et al. Course of Crohn's disease prior to establishment of the diagnosis. Z Gastroenterol 2008; 46(2): 187-92.
33. Burisch J, Pedersen N, Cukovic-Cavka S, et al. East-West gradient in the incidence of inflammatory bowel disease in Europe: the ECCO-EpiCom inception cohort. Gut 2014; 63(4): 588-97.
34. Beasley S, Cameron DS, McLain B, Davidson P, Stokes K. Diagnostic delay in Crohn's disease. Pediatr Surg Int 1992; 7(3): 171-3.
35. Vavricka SR, Spigaglia SM, Rogler G, et al. Systematic evaluation of risk factors for diagnostic delay in inflammatory bowel disease. Inflamm Bowel Dis. [Research Support, Non-U. S. Gov't]. 2012; 18(3): 496-505.
36. Hovde O, Moum BA. Epidemiology and clinical course of Crohn's disease: results from observational studies. World J Gastroenterol 2012; 18(15): 1723-31.
37. Fiorino G, Peyrin-Biroulet L, Naccarato P, et al. MRE Findings at Crohn's Disease Diagnosis: Disease Activity, Bowel Damage and Predictive Value for Long-Term Outcomes. Gastroenterology 2012; 142(5): S-579-S-80.
38. Kappos L, Freedman MS, Polman CH, et al. Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study. Lancet. [Randomized Controlled Trial Research Support, Non-U. S. Gov't]. 2007; 370(9585): 389-97.
39. Ramadas AV, Gunesh S, Thomas GA, Williams GT, Hawthorne AB. Natural history of Crohn's disease in a population-based cohort from Cardiff (1986-2003): a study of changes in medical treatment and surgical resection rates. Gut 2010; 59(9): 1200-6.
40. Lakatos PL, Golovics PA, David G, et al. Has there been a change in the natural history of Crohn's disease? Surgical rates and medical management in a population-based inception cohort from Western Hungary between 1977-2009. Am J Gastroenterol 2012; 107(4): 579-88.
41. Markowitz J, Grancher K, Kohn N, Lesser M, Daum F. A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn's disease. Gastroenterology. [Clinical Trial Multicenter Study Randomized Controlled Trial Research Support, Non-U. S. Gov't]. 2000; 119(4): 895-902.
42. Vernier-Massouille G, Balde M, Salleron J, et al. Natural history of pediatric Crohn's disease: a population-based cohort study. Gastroenterology. [Research Support, Non-U. S. Gov't]. 2008; 135(4): 1106-13.
43. Cosnes J, Bourrier A, Laharie D, et al. Early administration of azathioprine vs conventional management of Crohn's Disease: a randomized controlled trial. Gastroenterology [Comparative Study Randomized Controlled Trial Research Support, Non-U. S. Gov't]. 2013; 145(4): 758-65 e2; quiz e14-5.
44. Panes J, Lopez-Sanroman A, Bermejo F, et al. Early azathioprine therapy is no more effective than placebo for newly diagnosed Crohn's disease. Gastroenterology 2013; 145(4): 766-74 e1.
45. Schreiber S, Reinisch W, Colombel JF, et al. Subgroup analysis of the placebo-controlled CHARM trial: increased remission rates through 3 years for adalimumab-treated patients with early Crohn's disease. J Crohns Colitis 2013; 7(3): 213-21.
46. Colombel JF, Rutgeerts PJ, Sandborn WJ, et al. Adalimumab induces deep remission in patients with Crohn's disease. Clin Gastroenterol Hepatol 2014; 12(3): 414-22 e5.
47. Kugathasan S, Werlin SL, Martinez A, Rivera MT, Heikenen JB, Binion DG. Prolonged duration of response to infliximab in early but not late pediatric Crohn's disease. Am J Gastroenterol 2000; 95(11): 3189-94.
48. Walters TD, Kim MO, Denson LA, et al. Increased effectiveness of early therapy with anti-tumor necrosis factor-alpha vs an immunomodulator in children with Crohn's disease. Gastroenterology 2014; 146(2): 383-91.
49. Hyams J, Crandall W, Kugathasan S, et al. Induction and maintenance infliximab therapy for the treatment of moderate-tosevere Crohn's disease in children. Gastroenterology 2007; 132(3): 863-73; quiz 1165-6.
50. Zallot C, Peyrin-Biroulet L. Clinical risk factors for complicated disease: how reliable are they? Dig Dis 2012; 30 Suppl 3: 67-72.
51. Van Assche G, Dignass A, Panes J, et al. The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Definitions and diagnosis. J Crohns Colitis 2010; 4(1): 7-27.
52. Peyrin-Biroulet L, Fiorino G, Buisson A, Danese S. First-line therapy in adult Crohn's disease: who should receive anti-TNF agents? Nat Rev Gastroenterol Hepatol 2013; 10(6): 345-51.
53. Peyrin-Biroulet L, Billioud V, D'Haens G, et al. Development of the Paris definition of early Crohn's disease for diseasemodification trials: results of an international expert opinion process. Am J Gastroenterol 2012; 107(12): 1770-6.
54. Papp M, Lakatos PL. Serological studies in inflammatory bowel disease: how important are they? Curr Opin Gastroenterol 2014; 30(4): 359-64.
55. Israeli E, Grotto I, Gilburd B, et al. Anti-Saccharomyces cerevisiae and antineutrophil cytoplasmic antibodies as predictors of inflammatory bowel disease. Gut 2005; 54(9): 1232-6.
56. van Schaik FD, Oldenburg B, Hart AR, et al. Serological markers predict inflammatory bowel disease years before the diagnosis. Gut 2013; 62(5): 683-8.
57. Vasseur F, Sendid B, Jouault T, et al. Variants of NOD1 and NOD2 genes display opposite associations with familial risk of Crohn's disease and anti-saccharomyces cerevisiae antibody levels. Inflamm Bowel Dis 2012; 18(3): 430-8.
58. Hedin CR, Stagg AJ, Whelan K, Lindsay JO. Family studies in Crohn's disease: new horizons in understanding disease pathogenesis, risk and prevention. Gut 2012; 61(2): 311-8.
59. Sutherland AD, Gearry RB, Frizelle FA. Review of fecal biomarkers in inflammatory bowel disease. Dis Colon Rectum 2008; 51(8): 1283-91.
60. Langhorst J, Elsenbruch S, Koelzer J, Rueffer A, Michalsen A, Dobos GJ. Noninvasive markers in the assessment of intestinal inflammation in inflammatory bowel diseases: performance of fecal lactoferrin, calprotectin, and PMN-elastase, CRP, and clinical indices. Am J Gastroenterol 2008; 103(1): 162-9.
61. Sipponen T, Savilahti E, Kolho KL, Nuutinen H, Turunen U, Farkkila M. Crohn's disease activity assessed by fecal calprotectin and lactoferrin: correlation with Crohn's disease activity index and endoscopic findings. Inflamm Bowel Dis 2008; 14(1): 40-6.
62. Roseth AG, Schmidt PN, Fagerhol MK. Correlation between faecal excretion of indium-111-labelled granulocytes and calprotectin, a granulocyte marker protein, in patients with inflammatory bowel disease. Scand J Gastroenterol 1999; 34(1): 50-4.
63. Roseth AG, Fagerhol MK, Aadland E, Schjonsby H. Assessment of the neutrophil dominating protein calprotectin in feces. A methodologic study. Scand J Gastroenterol 1992; 27(9): 793-8.
64. van Rheenen PF, Van de Vijver E, Fidler V. Faecal calprotectin for screening of patients with suspected inflammatory bowel disease: diagnostic meta-analysis. BMJ 2010; 341: c3369.
65. Foell D, Wittkowski H, Roth J. Monitoring disease activity by stool analyses: from occult blood to molecular markers of intestinal inflammation and damage. Gut 2009; 58(6): 859-68.
66. Dai J, Liu WZ, Zhao YP, Hu YB, Ge ZZ. Relationship between fecal lactoferrin and inflammatory bowel disease. Scand J Gastroenterol 2007; 42(12): 1440-4.
67. Makinen H, Kautiainen H, Hannonen P, et al. Sustained remission and reduced radiographic progression with combination disease modifying antirheumatic drugs in early rheumatoid arthritis. J Rheumatol 2007; 34(2): 316-21.
68. Cush JJ. Early rheumatoid arthritis-is there a window of opportunity? J Rheumatol Suppl 2007; 80: 1-7.
69. Aletaha D, Smolen J, Ward MM. Measuring function in rheumatoid arthritis: Identifying reversible and irreversible components. Arthritis Rheum 2006; 54(9): 2784-92.
70. Len CA, Terreri MT, Puccini RF, et al. Development of a tool for early referral of children and adolescents with signs and symptoms suggestive of chronic arthropathy to pediatric rheumatology centers. Arthritis Rheum 2006; 55(3): 373-7.
71. Ricci C, Lanzarotto F, Lanzini A. The multidisciplinary team for management of inflammatory bowel diseases. Dig Liver Dis 2008; 40 Suppl 2: S285-8.
72. Mawdsley JE, Irving PM, Makins RJ, Rampton DS. Optimizing quality of outpatient care for patients with inflammatory bowel disease: the importance of specialist clinics. Eur J Gastroenterol Hepatol 2006; 18(3): 249-53.
73. Panes J, O'Connor M, Peyrin-Biroulet L, Irving P, Petersson J, Colombel JF. Improving quality of care in inflammatory bowel disease: What changes can be made today? J Crohns Colitis 2014 pii: S1873-9946(14)00212-8.
74. Kollensperger M, Geser F, Seppi K, et al. Red flags for multiple system atrophy. Mov Disord 2008; 23(8): 1093-9.
75. M S, Lamont AC, Alias NA, Win MN. Red flags in patients presenting with headache: clinical indications for neuroimaging. Br J Radiol 2003; 76(908): 532-5.
76. Sizer PS, Jr., Brismee JM, Cook C. Medical screening for red flags in the diagnosis and management of musculoskeletal spine pain. Pain Pract 2007; 7(1): 53-71.
77. Pimentel M, Chang M, Chow EJ, et al. Identification of a prodromal period in Crohn's disease but not ulcerative colitis. Am J Gastroenterol 2000; 95(12): 3458-62.
78. Danese S, Fiorino G, Peyrin-Biroulet L, et al. Development of red flags for early referral of adults with symptoms and signs suggestive of Crohn's disease: an IOIBD initiative. J Crohns Colitis 2014; Vol. 8 Supplement 1: S28.